Progress of research on dyslipidemia accompanied by nephrotic syndrome

Nephrotic syndrome is a relatively common clinical disease. Associated dyslipidemia is a risk factor for the occurrence and development of cardiovascular and renal diseases that might gradually develop into atherosclerosis, glomerulosclerosis or tubulointerstitial injury. It also confers an elevated...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Min Tao, Hai-Ping Wang, Jing Sun, Jing Tian
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2020
Materias:	Nephrotic syndrome Dyslipidemia Atherosclerosis Glomerulosclerosis Statins Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/cda45ff6769e4a60b3a9f38a2f606d98
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cda45ff6769e4a60b3a9f38a2f606d98
record_format	dspace
spelling	oai:doaj.org-article:cda45ff6769e4a60b3a9f38a2f606d982021-12-02T15:57:20ZProgress of research on dyslipidemia accompanied by nephrotic syndrome2095-882X10.1016/j.cdtm.2020.03.002https://doaj.org/article/cda45ff6769e4a60b3a9f38a2f606d982020-09-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X20300311https://doaj.org/toc/2095-882XNephrotic syndrome is a relatively common clinical disease. Associated dyslipidemia is a risk factor for the occurrence and development of cardiovascular and renal diseases that might gradually develop into atherosclerosis, glomerulosclerosis or tubulointerstitial injury. It also confers an elevated risk of complications such as thromboembolism. If not properly controlled over the long term, dyslipidemia will become a key factor in a poor prognosis. Furthermore, dyslipidemia correlates with an increase in hepatic compensatory synthetic lipoprotein levels and a decrease in lipoprotein clearance, which can be sourced to the downregulation of hepatic and lipoprotein lipase activities in endothelial cells, muscle, and adipose tissue, and clinically characterized as hypertriglyceridemia or hypercholesterolemia. However, further investigations into the mechanism(s) of dyslipidemia are needed, with the resultant detailed perspectives and analyses substantially aiding the further development of treatment guidelines. Currently, statins represent the most popular type of pharmaceutical intervention because they lower hepatic cholesterol production and promote the absorption of low-density lipoprotein-cholesterol from the bloodstream, followed by second-line and other potential therapies to regulate the expression of specific receptors.Min TaoHai-Ping WangJing SunJing TianKeAi Communications Co., Ltd.articleNephrotic syndromeDyslipidemiaAtherosclerosisGlomerulosclerosisStatinsMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 6, Iss 3, Pp 182-187 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Nephrotic syndrome Dyslipidemia Atherosclerosis Glomerulosclerosis Statins Medicine (General) R5-920
spellingShingle	Nephrotic syndrome Dyslipidemia Atherosclerosis Glomerulosclerosis Statins Medicine (General) R5-920 Min Tao Hai-Ping Wang Jing Sun Jing Tian Progress of research on dyslipidemia accompanied by nephrotic syndrome
description	Nephrotic syndrome is a relatively common clinical disease. Associated dyslipidemia is a risk factor for the occurrence and development of cardiovascular and renal diseases that might gradually develop into atherosclerosis, glomerulosclerosis or tubulointerstitial injury. It also confers an elevated risk of complications such as thromboembolism. If not properly controlled over the long term, dyslipidemia will become a key factor in a poor prognosis. Furthermore, dyslipidemia correlates with an increase in hepatic compensatory synthetic lipoprotein levels and a decrease in lipoprotein clearance, which can be sourced to the downregulation of hepatic and lipoprotein lipase activities in endothelial cells, muscle, and adipose tissue, and clinically characterized as hypertriglyceridemia or hypercholesterolemia. However, further investigations into the mechanism(s) of dyslipidemia are needed, with the resultant detailed perspectives and analyses substantially aiding the further development of treatment guidelines. Currently, statins represent the most popular type of pharmaceutical intervention because they lower hepatic cholesterol production and promote the absorption of low-density lipoprotein-cholesterol from the bloodstream, followed by second-line and other potential therapies to regulate the expression of specific receptors.
format	article
author	Min Tao Hai-Ping Wang Jing Sun Jing Tian
author_facet	Min Tao Hai-Ping Wang Jing Sun Jing Tian
author_sort	Min Tao
title	Progress of research on dyslipidemia accompanied by nephrotic syndrome
title_short	Progress of research on dyslipidemia accompanied by nephrotic syndrome
title_full	Progress of research on dyslipidemia accompanied by nephrotic syndrome
title_fullStr	Progress of research on dyslipidemia accompanied by nephrotic syndrome
title_full_unstemmed	Progress of research on dyslipidemia accompanied by nephrotic syndrome
title_sort	progress of research on dyslipidemia accompanied by nephrotic syndrome
publisher	KeAi Communications Co., Ltd.
publishDate	2020
url	https://doaj.org/article/cda45ff6769e4a60b3a9f38a2f606d98
work_keys_str_mv	AT mintao progressofresearchondyslipidemiaaccompaniedbynephroticsyndrome AT haipingwang progressofresearchondyslipidemiaaccompaniedbynephroticsyndrome AT jingsun progressofresearchondyslipidemiaaccompaniedbynephroticsyndrome AT jingtian progressofresearchondyslipidemiaaccompaniedbynephroticsyndrome
_version_	1718385358402486272

Progress of research on dyslipidemia accompanied by nephrotic syndrome

Ejemplares similares